Fibrose pulmonaire et cancer pulmonaire : entre complémentarités et spécificités [Pulmonary fibrosis and lung cancer: between complementarities and specificities]
Fiche du document
16 novembre 2022
- doi: 10.53738/REVMED.2022.18.804.2162
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2022.18.804.2162
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/36382977
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_69C8043714C20
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-05-16 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Lung cancerCiter ce document
J. Rey Cobo et al., « Fibrose pulmonaire et cancer pulmonaire : entre complémentarités et spécificités [Pulmonary fibrosis and lung cancer: between complementarities and specificities] », Serveur académique Lausannois, ID : 10.53738/REVMED.2022.18.804.2162
Métriques
Partage / Export
Résumé
Lung cancer is the leading cause of cancer mortality in the developed world. Diffuse fibrosing interstitial lung disease (ILD) consist of a heterogeneous group that includes idiopathic pulmonary fibrosis (IPF). Diffuse ILD is a risk factor for the development of lung cancer which on its own is associated with an increased risk of morbidity and mortality. Despite common mechanisms between fibrogenesis and carcinogenesis, the underlying pathogenesis of lung cancer and fibrosis overlap is poorly understood. The clinical management of these patients remains a medical challenge requiring a multidisciplinary approach, particularly in view of the risk of acute exacerbation of fibrosing ILD following most lung cancer treatments, leading to a considerable negative outcome on overall prognosis.